IMPACT Therapeutics, Inc (HKG:7630)

Market Cap	3.93B
Revenue (ttm)	136.46M +14.0%
Net Income	-297.86M
EPS	-1.24
Shares Out	282.46M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,627,000
Open	14.10
Previous Close	13.93
Day's Range	13.70 - 15.11
52-Week Range	10.31 - 47.98
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Dec 1, 2026

About IMPACT Therapeutics

IMPACT Therapeutics, Inc., a biotechnology company, researches and develops synthetic lethality (SL)-based precision anti-cancer therapies in China and internationally. The company offers a product, (IMP4297) Senaparib, a PARP1/2 inhibitor that is used for 1L maintenance therapy for ovarian cancer (OC). Its pipeline products includes IMP1734, a next-generation poly (ADP-ribose) polymerase (PARP)1 selective inhibitor evaluated as monotherapy, which is in Phase I/II clinical trial for the treatment of advanced solid tumors; IMP9064, an ataxia tel...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2009
• Employees: 88
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 7630

Financial Performance

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 30, 2026

Data Sources Report a data error